These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26296953)

  • 1. Epigenetic approaches to overcoming chemotherapy resistance.
    Strauss J; Figg WD
    Lancet Oncol; 2015 Sep; 16(9):1013-1015. PubMed ID: 26296953
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
    Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
    Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
    Oronsky B; Scicinski J; Cabrales P; Minchinton A
    Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RRx-001, A novel dinitroazetidine radiosensitizer.
    Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
    Invest New Drugs; 2016 Jun; 34(3):371-7. PubMed ID: 26841903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
    Scicinski J; Fisher G; Carter C; Cho-Phan C; Kunz P; Ning S; Knox S; Oronsky B; Caroen S; Parker C; Fanger G; Reid T
    Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.
    Brzezniak C; Oronsky B; Scicinski J; Caroen S; Cabrales P; Dean Abrouk N; Kim MM; Brown JF; Reid TR; Larson C; Oronsky A; Day R; Degesys A; Carter CA
    Oncol Res Treat; 2016; 39(11):720-723. PubMed ID: 27855386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
    Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
    Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic targeting therapies to overcome chemotherapy resistance.
    Balch C; Nephew KP
    Adv Exp Med Biol; 2013; 754():285-311. PubMed ID: 22956507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
    Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM
    Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic perspectives on cancer chemotherapy response.
    Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W
    Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic discoveries propagate new epigenetic drugs.
    Garber K
    J Natl Cancer Inst; 2012 Feb; 104(3):174-6. PubMed ID: 22271768
    [No Abstract]   [Full Text] [Related]  

  • 13. Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
    Carter CA; Zeman K; Day RM; Richard P; Oronsky A; Oronsky N; Lybeck M; Scicinski J; Oronsky B
    Oncotarget; 2016 Jun; 7(26):40781-40791. PubMed ID: 27007055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 15. Epigenetic therapies reach main street.
    Bates SE
    Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
    [No Abstract]   [Full Text] [Related]  

  • 16. Epigenetic inhibitors.
    Verma M; Banerjee HN
    Methods Mol Biol; 2015; 1238():469-85. PubMed ID: 25421675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors.
    Yang AS; Yang BJ
    Epigenomics; 2016 Jan; 8(1):9-12. PubMed ID: 26698294
    [No Abstract]   [Full Text] [Related]  

  • 18. Zebularine: a candidate for epigenetic cancer therapy.
    Bradbury J
    Drug Discov Today; 2004 Nov; 9(21):906-7. PubMed ID: 15501719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecular modulators of cancer-associated epigenetic mechanisms.
    Itoh Y; Suzuki T; Miyata N
    Mol Biosyst; 2013 May; 9(5):873-96. PubMed ID: 23511667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epigenetic cancer drugs and their role in anticancer therapy].
    Klener P
    Vnitr Lek; 2013 Jun; 59(6):463-5. PubMed ID: 23808740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.